Ernexa Therapeutics Inc. Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax
Ernexa Therapeutics Inc. (ERNA) reported Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax of $46.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax · last filed 2013-03-29
- Ernexa Therapeutics Inc. defined benefit plan, amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss, before tax for fiscal 2012 was $46.00K.
- Ernexa Therapeutics Inc. defined benefit plan, amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss, before tax for fiscal 2011 was -$60.00K.
| Period end | Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax 12 month |
|---|---|
| 2012-12-31 | $46.00K 10-K · filed 2013-03-29 |
| 2011-12-31 | -$60.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |